Answer
Retsevmo (selpercatinib) is indicated as monotherapy for adults with advanced RET fusion-positive non-small cell lung cancer who have not previously been treated with a RET inhibitor.
Sources for this answer
- Retsevmo 40mg and 80mg film-coated tabletsEli Lilly and Company Limited · emc · SmPC §4.1 Therapeutic Indications · Version 3Document updated
Sources checked